1stOncology™: Cancer Intelligence Service – Page 9869 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Biosceptre secures £7m. to boost novel CAR T therapy

On March 8, 2021 Biosceptre reported the securing of £7m. (US$9.6m.) in funds to boost development of its nfP2X7-targeted CAR T program – a new generation of therapy with the potential to treat a broad range of haematologic and solid tumour malignancies (Press release, Biosceptre, MAR 8, 2021, View Source;utm_medium=rss&utm_campaign=biosceptre-secures-7m-to-boost-novel-car-t-therapy [SID1234577403]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The funding, drawn from Norcliffe Capital in Europe and Jungle Capital in Australia, will help Biosceptre push it’s unique lead program towards clinical trials.

"We are really pleased by this fund raise as it reaffirms confidence in our ground-breaking nfP2X7-targeted therapies, and the drastic difference they could make to the lives of thousands of cancer patients, world-wide," explained said Mr Gavin Currie, CEO of Biosceptre.

"The funding will help propel our CAR T program through the optimisation and preclinical stage, towards manufacturing and potential first in-human studies."

"In parallel with our CAR T program we will further the development of our monoclonal antibody therapeutic program too."

nfP2X7 is a tumour-specific target, discovered by Biosceptre, that’s found on a wide range of cancers, both haematological and solid. Studies have shown that it retains critical signalling capabilities that support cancer cell survival and possesses novel epitopes that are available for antibody binding. Importantly, these aren’t detected at the surface of functional P2X7. Targeting cancer cells via these nfP2X7 epitopes offers great specificity – and forms the basis of Biosceptre’s technology.

Driven by Nobel prize-winning science leadership, Biosceptre’s innovative research and therapeutics are supported by ongoing collaborations with global experts and major research institutes, such as The University of Sydney, Universiy of Technology, Sydney and The Children’s Medical Research Institute

Novo Nordisk A/S – Share repurchase programme

On March 8, 2021 Novo Nordisk reported that initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules") (Press release, Novo Nordisk, MAR 8, 2021, View Source [SID1234577316]). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 3 February 2021.

Under the programme initiated 3 February 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 3 February 2021 to 3 May 2021.

Since the announcement as of 1 March 2021, the following transactions have been made:

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 1,318 B shares in the period from 1 March 2021 to 5 March 2021. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 41,456,629 B shares of DKK 0.20 as treasury shares, corresponding to 1.8% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12- month period beginning 3 February 2021. As of 5 March 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 2,554,017 B shares at an average share price of DKK 447.07 per B share equal to a transaction value of DKK 1,141,817,376.

Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat

On March 8, 2021 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, reported that it will participate in a fireside chat during the H.C. Wainwright Virtual Global Life Sciences conference. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion (Press release, Novavax, MAR 8, 2021, View Source [SID1234576335]).

Fireside Chat details:
Date: Tuesday, March 9, 2021
Time: Available on-demand starting at 7:00 a.m. Eastern Time (ET)
Participants: Gregory M. Glenn, M.D., President, Research and Development and John Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer
A replay of the recorded fireside session will be available through the events page of the Company’s website at ir.novavax.com for 90 days.

DiaMedica Therapeutics to Participate at Upcoming Investor Conferences

On March 8, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, reported that the company will participate in three upcoming investor conferences. Details of the company’s participation are as follows (Press release, DiaMedica, MAR 8, 2021, View Source [SID1234576334]):

33rd Annual Roth Conference
Details: DiaMedica Therapeutics management will deliver a fireside chat and participate in 1-on-1 meetings
Company conference participation date: March 15th, 2021
Oppenheimer’s 31st Annual Healthcare Conference
Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings
Company conference participation date: March 16th, 2021
Maxim’s Emerging Growth Conference
Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings
Company conference participation date: March 17th, 2021

vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

On March 8, 2021 vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, reported its participation in the H.C. Wainwright Global Life Sciences Conference held virtually March 9-10, 2021 (Press release, vTv Therapeutics, MAR 8, 2021, View Source [SID1234576333]).

The company will be providing a general company update through a virtual presentation that will be available on demand for conference attendees beginning on March 9, 2021. Company management will also be meeting with members of the investment community during one-on-one virtual meetings.